Life sciences tools company Agilent Technologies (NYSE:A) announced better-than-expected revenue in Q1 CY2026 (fiscal Q2), with sales up 10% year on year to ...
Agilent Technologies (NYSE:A) raised its fiscal 2026 outlook after reporting stronger-than-expected second-quarter results, with management pointing to broad-based demand, instrument replacement momentum, pricing actions and operational gains from its Ignite operating system.
CEO Padraig McDonnell
Life sciences tools company Agilent Technologies (NYSE:A) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 10% year on y...
Life sciences tools company Agilent Technologies (NYSE:A) will be reporting results this Wednesday after the bell. Here’s what investors should know. Agilent...
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whet...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Over the past six months, Agilent’s stock price fell to $118.28. Shareholders have lost 16.7% of their capital, which is disappointing considering the S&P 50...
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
The financial heart of the technology sector shifted toward the subatomic this week as Xanadu Quantum Technologies (NASDAQ: XNDU) officially began trading on the Nasdaq. Marking a historic milestone as the world’s first public "pure-play" photonic quantum computing company, the Canadian-headquartered firm completed its business combination with Crane Harbor
Looking back on research tools & consumables stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Agilent (NYSE:A) and its pee...
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...
Agilent expects the deal to boost revenue growth and margins in the first year, with the transaction projected to add to earnings per share about 12 months after closing.
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings
